Patent ID: 8912217

Claim:
A drug system comprising: a first drug product comprising a first drug substance consisting essentially of a first amine containing pharmaceutically active compound with an immediate release profile of said first amine containing pharmaceutically active compound from said first drug substance at gastrointestinal pH to reach a therapeutic level; and a second drug product comprising a second drug substance wherein said second drug substance has a slower release profile of racemic or single isomer ritalinic acid or phenethylamine from said second drug substance at gastrointestinal pH suitable for maintaining said therapeutic level wherein said second drug substance consist of A-B-C wherein said A-B-C is defined: A is said second amine containing pharmaceutically active compound selected from said racemic or single isomer of ritalinic acid, methylphenidate or phenethylamine; B is a bidentate linking group defined by the formula: wherein Y 1 and Y 2 are independently selected from oxygen; R 10 and R 11 are absent; G 1 and G 2 independently represent ionically bound groups A and C R 12 and R 13 are independently selected from hydrogen, alkyl or 1-6 carbons, alkylacyl of 1-8 carbons or arylacyl of 7-15 carbons; R 14 will replace one of R 15 , R 16 , R 17 or R 18 and one of R 19 , R 20 , R 21 or R 22 and is an alkyl or branched alkyl of 1-10 carbons, aryl, arylalkyl of 7-15 carbons and wherein R 14 may include at least one optically active carbon; and R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 and R 22 , are independently selected from hydrogen, alkyl of 1-6 carbons, and wherein adjacent groups may be taken together to form a cyclic alkyl or cyclic aryl moiety; and C is an amine which is other than ritalinic acid, phenethylamine, or methylphenidate.